Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04255498
Other study ID # 4987.84
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date October 30, 2017
Est. completion date August 30, 2020

Study information

Verified date January 2020
Source South Florida Veterans Affairs Foundation for Research and Education
Contact Fanny Collado, RN
Phone 305-575-7000
Email fanny.collado@va.gov
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigator proposes to perform a Phase I study assessing safety, efficacy, and biomarker response to the therapeutic interventions of Etanercept followed by mifepristone for veterans with Gulf War Illness. The investigator will conduct and repeat the exercise challenge before treatment and on therapy to assess the impact of the interventions on homeostatic regulation and the dynamic model identified in prior studies.


Description:

In the Investigator's prior work, the investigator used an exercise stress model (rest, peak oxygen consumption oxygen uptake, and 7 follow-up sampling points) to measure the mediators of relapse in the context of their interactive homeostatic networks. The investigator surveyed the response of genes and blood-borne biomarkers in order to interrogate and map the regulation of neuro-endocrine-autonomic-immune function in these subjects as compared to GW era sedentary healthy controls. This study is the first to test in the GWI human system of the impact of interventions that hope to permanently re-set the key pathway(s) involved in maintaining a "sick" homeostatic network in Gulf War Illness, discovered in our prior CDMRP and VA funded projects. An open-label Phase I study will be performed with Etanercept (once a week for 4 weeks) followed by mifepristone (once a day for 7 days), followed by a 10-week observation to assess safety, efficacy and biomarker response to maximal exercise. The impact of the interventions will be measured on current computational modeling of dynamic response GWI illness mediators at onset, at 6 weeks (on completion of the medication regimen) and 4 months after baseline; using 20 GWI patients. The response during and after an exercise challenge will be assessed followed by map the homeostatic networks in play over the 24 hours post-exercise in subjects before treatment, after completing the second treatment (week 6) and 4 months after initiating treatment (week 16).


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date August 30, 2020
Est. primary completion date August 15, 2019
Accepts healthy volunteers No
Gender Male
Age group 40 Years to 70 Years
Eligibility Inclusion Criteria:

- Male Veterans who were deployed in 1990 -1991 Gulf War.

- Veterans who currently meet the Kansas Gulf War Study Case Definition for Gulf War Illness.

- Veterans who were in good health based on medical history prior to 1990.

- Veterans who are between 40 to 70 years old

- Veterans who currently do not have exclusionary diagnoses that could reasonably explain the symptoms of their fatiguing illness and their severity.

Exclusion Criteria:

- Major depression with psychotic or melancholic features

- Schizophrenia

- Bipolar disorder

- Delusional disorders

- Dementias of any type

- History or current alcohol abuse

- History or current drug abuse

- Organ failure

- Transplant

- Defined rheumatologic

- Inflammatory disorders

- HIV

- Hepatitis B and C

- Primary sleep disorders

- Steroids

- Immunosuppressives

- Medications that impact immune function such as Enbrel or Methotrexate

- Tuberculosis or past history of tuberculosis exposure, as documented by PPD positivity

Study Design


Intervention

Drug:
Etanercept
Perform Phase I study of etanercept (50 mg, once a week for 4 weeks), followed by mifepristone (300 mg, once a day for 7 days), followed by a 10 week observation period and assessment of safety, efficacy and biomarker response to therapy. Perform dynamic modeling studies before and after 5 weeks of therapy, repeating the method used previously, in order to document the response to exercise and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time with blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies.
Mifepristone
Perform Phase I study of etanercept (50 mg, once a week for 4 weeks), followed by mifepristone (300 mg, once a day for 7 days), followed by a 10 week observation period and assessment of safety, efficacy and biomarker response to therapy. Perform dynamic modeling studies before and after 5 weeks of therapy, repeating the method used previously, in order to document the response to exercise and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time with blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies.

Locations

Country Name City State
United States Miami VA Healthcare System Miami Florida

Sponsors (3)

Lead Sponsor Collaborator
South Florida Veterans Affairs Foundation for Research and Education Nova Southeastern University, United States Department of Defense

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Biomarker response to therapy using Cytokine panel Goal is decreased inflammation Change from Baseline at 6 weeks and 16 weeks
Secondary Biomarker response too therapy using VO2 exercise test Goal is that both will prove safe for use in GWI patients Change from Baseline at 6 weeks and 16 weeks]
See also
  Status Clinical Trial Phase
Recruiting NCT04254627 - TNF and Glucocorticoid Antagonist for GWI Associated Multi-symptom Disease Homeostasis Reset Phase 1
Terminated NCT02011542 - Probiotic (VSL #3) for Gulf War Illness Phase 2/Phase 3
Recruiting NCT03078530 - Probiotic (Visbiome) for Gulf War Illness Phase 2/Phase 3
Recruiting NCT04058275 - "Immunomodulation in GWI (Phlebotomy)"
Completed NCT02782780 - Cognitive Behavioral Therapy for Insomnia for Gulf War Illness N/A
Recruiting NCT02983734 - D-cycloserine: A Novel Treatment for Gulf War Illness (GWDCS) Phase 2
Recruiting NCT05972291 - Mechanisms of Gulf War Illness N/A
Recruiting NCT04046536 - rTMS in Alleviating Pain and Co-Morbid Symptoms in Gulf War Veterans Illness (GWVI) N/A
Recruiting NCT04182659 - Long Term Efficacy of Neuronavigation Guided rTMS in Alleviating Gulf War Illness Related Headaches and Pain Symptoms N/A
Recruiting NCT05377242 - Curcumin, Resveratrol, and Stinging Nettle as Treatments for GWI N/A
Recruiting NCT05675878 - Confirmation of Diet as a Treatment for Gulf War Illness Phase 3
Recruiting NCT05736146 - Validating Gulf War Illness Blood Biomarkers
Not yet recruiting NCT05820893 - Resistant Potato Starch to Alleviate GWI Phase 2
Terminated NCT01846182 - Research Examining Gulf War Illness in Our Nations Service Members Phase 2
Active, not recruiting NCT05252949 - OEA for Targeting Lipid Metabolism in GWI N/A
Completed NCT02378025 - Treating Chronic Pain in Gulf War Illness N/A
Completed NCT02865460 - Coenzyme Q10 Phase III Trial in Gulf War Illness Phase 3
Completed NCT02909686 - Effects of Botanical Microglia Modulators in Gulf War Illness N/A
Completed NCT01291758 - Exercise in Gulf War Illness (GWI)
Completed NCT01011348 - Q10 for Gulf War Veterans N/A